Lifetech CeraFlex™ Post-Market Surveillance Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Study Completion Date

2020-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this multi-center, non-interventional, prospective, post-market clinical study is to collect real world data on patient outcomes and evaluate the procedural success and performance of the Lifetech CeraFlex™ occluders for patients with secundum type Atrial Septum Defect (ASD), Patent Foramen Ovale (PFO) or Patent Ductus Arteriosus (PDA).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CeraFlex PFO Closure System PMCF Study

NCT06120270

Patent Foramen Ovale

RECRUITING

Lifetech CeraFlex™ ASD Closure System Post-Market Clinical Follow-Up

NCT05887700

Atrial Septal Defect

RECRUITING

Lifetech Cera™ PFO Occluder Post-Market Clinical Follow-Up

NCT05893758

Patent Foramen Ovale PFO

COMPLETED

Cera™ VSD Occluder Post Market Clinical Follow-up

NCT05939713

Ventricular Septal Defect

COMPLETED

Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve

NCT01808274

Aortic Valve Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is designed as a post-market, prospective, multi-center, non-interventional clinical study to collect data regarding procedural success, clinical performance and cost-effectiveness of the Lifetech CeraFlex™ occluders in patients with secundum ASD, PFO and PDA.

Patients will be recruited in up to 12 investigational centers located in Europe and the Middle East.

To avoid bias in the study population the following measures will be taken:

* All sponsor or designee and external study personnel will be trained on the latest version of the Clinical Investigation Plan (CIP) and related study materials.
* Patients will be screened to confirm study eligibility with pre-defined inclusion/exclusion criteria prior to enrollment.
* This study will follow consecutive screening and enrollment.

The study will enroll 120 patients. The patient population will consist of up to approximately 40 consecutive enrolled patients with a confirmed secundum type ASD, up to approximately 40 enrolled patients with PFO and up to approximately 40 enrolled patients with PDA resulting in a significant shunt and in need of an intervention. These estimated upper limits per therapy group can however be exceeded depending on the enrollment trend, to account for a minimum of 10 patients to be enrolled per therapy group and a total study population of 120 enrolled patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patent Foramen Ovale Atrial Septal Defect Patent Ductus Arteriosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CeraFlex occluder

The Lifetech CeraFlex™ study is a triple-arm study.

Group Type OTHER

CeraFlex

Intervention Type DEVICE

The Lifetech CeraFlex™ study is a triple-arm study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CeraFlex

The Lifetech CeraFlex™ study is a triple-arm study.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Confirmed ASD, PFO or PDA and patient characteristics consistent with the corresponding IFU and sizing guidelines;
2. The patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has signed the applicable Consent Form, approved by the appropriate Ethics Committee (EC)/IRB (where required);
3. The patient agrees to comply with requirements of the study including the 12 months followup.

Exclusion Criteria

Patients will be excluded if any of the following conditions apply:

1. Any contra-indication mentioned in the corresponding IFU;
2. Currently participating in another investigational drug- or device study.

Eligible Sex

ALL

Accepts Healthy Volunteers

No